La vendita allo scoperto per Medtronic dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Medtronic. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Medtronic (NYSE:MDT) Azioni, Report sulle vendite allo scoperto

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

MEDTRONIC ORD

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

The Symplicity &#x2122; blood pressure procedure offers patients a new adjunct approach to lowering blood pressure&nbsp;
GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122;&nbsp;renal denervation (RDN) catheter, used in the Symplicity&#x2122;&nbsp;blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

Biotech

General

CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025

<a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk" title="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk">https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk</a>

Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT

Company commits to advancing clinical data for Symplicity&#x2122; with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial
GALWAY, Ireland and WASHINGTON, Oct.&nbsp;28, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity&#x2122; Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics&nbsp;Conference (TCT).

Medtronic Announces Long-Term Data From Its SPYRAL HTN-ON MED Clinical Trial That Showed Subjects Who Underwent Radiofrequency Renal Denervation With The Symplicity Spyral Renal Denervation System Had Greater Reductions In 24-Hr ABPM, And OSBP Compared To Sham Patients At 2-Years

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $94.73, a high estimate of $106.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 3.64% from the previous average price target of $91.40.
<img src="https://www.benzinga.com/files/images/story/2024/1729886461_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Medtronic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$93.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Medtronic's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Medtronic's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>Unveiling the Story Behind Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>A Deep Dive into Medtronic's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Medtronic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.77% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Medtronic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.58.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Medtronic Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Medtronic

Medtronic Gains FDA Approval For Affera Mapping And Ablation System With Sphere-9 Catheter; First All-In-One HD Mapping And Dual Energy Ablation Device For Treating AFib And Atrial Flutter

WIIM

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and raises the price target from $90 to $93.

Truist Securities Maintains Hold on Medtronic, Raises Price Target to $93

Stryker (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities. Still, recent months in 2024 have been particularly active for Stryker when it comes to acquisitions.
Since the beginning of July, the company has closed on or announced purchases of five companies. I&#39;ll dive into what Stryker does and the most important of these acquisitions to help determine whether they make the stock a buy.
<h2>Stryker: A Highly Diversified Medical Device Company</h2>
Stryker has two reportable segments: MedSurg &amp; Neurotechnology and Orthopedics &amp; Spine. MedSurg provides surgical tools, including minimally invasive devices. These include small cameras used in surgeries. Neurotechnology offers tools for skull and brain surgeries, including stroke treatments. In 2023, this segment accounted for 58% of the company&#39;s total revenue.
The other segment revolves around bodily implants. Orthopedics includes hip, knee, and shoulder implants to replace these joints. The company&#39;s Mako system provides robotics-assisted replacement of these joints. It has similarities to Intuitive Surgical&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) da Vinci system, but the two specialize in different treatment areas.
This segment also provides trauma and extremity implants. Trauma refers to implants used to help repair large broken bones like those in the arms and legs. Extremity implants help repair joints and bones in the hands and feet. It also provides spinal implants. This segment accounted for 42% of revenue in 2023.
<h2>Breaking Down Stryker&#39;s Recent Acquisitions</h2>
I&#39;ll focus on two of Stryker&#39;s recent acquisitions, NICO and Care.ai.
The NICO acquisition now gives Stryker ownership of minimally invasive devices that are used to surgically treat intracerebral hemorrhage (ICH). ICH is the deadliest form of stroke and affects 3.4 million people annually. The current care standard for ICH is medical management. This means doctors keep the patient stable while they hope the body can remove the blood clot over time.
The New England Journal of Medicine published a study where the NICO technology cut patient mortality rates by nearly in half compared to medical management. Additionally, the patients treated using NICO had significantly better quality of life outcomes. Given the large number of patients who suffer from ICH and the impressive efficacy of NICO technology, this feels like a strong purchase.
The care.ai purchase allows Stryker to offer its hospital and health provider customers tools to more efficiently monitor the status of patients. This allows these customers to make better decisions about how to allocate resources across patients. For example, patients can use AI chatbots to assess their condition. They can check whether they need urgent medical care or not.
The company&#39;s technology can also improve the monitoring of patients while they are in the healthcare facility. Its &quot;smart room&quot; technology involves installing sensors that use AI to better monitor the condition of patients. These features can help Stryker&#39;s customers better prioritize staff and resources in a facility. They aim to improve patient outcomes and satisfaction.
Overall, this could create value for Stryker customers. However, I am less sold on it compared to NICO. Just because a company uses AI in its offerings doesn&#39;t mean it is truly providing differentiated value compared to what already exists.
In the near term, these acquisitions will not impact the company&#39;s financial results. This is likely the case, as the financial details of these acquisitions were not disclosed. The Securities and Exchange Commission (SEC) does not require publicly traded companies to disclose these details unless the acquisitions are expected to have a material impact on the company&#39;s financial statements. Still, they could definitely create value for the company over the long term.
I especially like the NICO acquisition, and it could be a good thing that the company did not have to disclose the price. It might suggest that they were able to acquire the asset at a reasonable cost.
<h2>Stryker Is Expected to See Robust Earnings Growth</h2>
Analysts expect strong earnings growth over the next two years, especially versus its peers. Analysts expect a 12% annual growth in trailing twelve months earnings per share. That is over double the rate of one of its main competitors, Medtronic (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>).
Two Wall Street analysts raised their price target for Stryker in October. Their average price target implies an upside of 7% for the stock. Stryker remains a strong player in its industry, but these acquisitions don&#39;t move the needle on the stock for me right now.
The article &quot;<a href="https://www.marketbeat.com/originals/strykers-acquisition-spree-double-digit-growth-on-the-horizon/">Stryker&#39;s Acquisition Spree: Double-Digit Growth on the Horizon</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Offerings

ISRG

Stryker's Acquisition Spree: Double-Digit Growth on the Horizon

RBC Capital analyst Shagun Singh upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Sector Perform to Outperform and raises the price target from $98 to $105.

Upgrades

RBC Capital Upgrades Medtronic to Outperform, Raises Price Target to $105

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.33, along with a high estimate of $106.00 and a low estimate of $85.00. Observing a 2.71% increase, the current average has risen from the previous average price target of $90.87. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421229_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>All You Need to Know About Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin excels beyond industry benchmarks, reaching 13.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Assess Medtronic: What You Need To Know

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Sector Perform and raises the price target from $92 to $98.

RBC Capital Maintains Sector Perform on Medtronic, Raises Price Target to $98

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) initiated a recall Friday to address potential battery life issues with <a href="https://www.benzinga.com/pressreleases/24/10/n41181874/voluntary-recall-notifying-medtronic-insulin-pump-users-of-potential-risks-of-shortened-pump-batte" target="_blank" rel="noreferrer noopener">its insulin pumps</a>.
As of July 31, the company has advised customers to pay close attention to their pumps&#8217; battery alerts and alarms.
The action follows reports of shortened battery life, which Medtronic linked to pumps that had been dropped or impacted.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40737587/medtronic-recalls-some-video-laryngoscopes-due-to-increased-risk-for-battery-overheat-explosion" rel="noreferrer noopener">Medtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, Explosion</a>.
This damage to internal electrical components may result in the pump stopping insulin delivery earlier than expected, posing risks such as hyperglycemia (high blood sugar) or diabetic ketoacidosis (DKA).
DKA is a complication of diabetes that occurs when the body doesn&#8217;t have enough insulin to use blood sugar for energy.
Medtronic&#8217;s investigation revealed that even a single drop could significantly reduce battery life, either immediately or over time.
This issue persists within the MiniMed 600 and 700 pumps even after the battery is replaced.
Additionally, battery alerts and alarms may not provide the usual warning before the pump stops insulin delivery, increasing the need for users to replace the battery as soon as the &#8220;Low Battery Pump&#8221; alarm is triggered.
Medtronic strongly advises users to carry extra AA lithium, alkaline, or fully charged NiMH batteries as a precaution.
The issue is serious, as Medtronic has received 170 reports of hyperglycemia exceeding 400 mg/dL and 11 reports of DKA in the U.S. between January 2023 and September 2024, possibly related to this problem.
The FDA has classified the action as a class I recall. That&#8217;s the most serious type of recall due to potential adverse health consequences.
Medtronic users who experience shortened battery life should contact their local support team to assess whether a replacement pump is needed.
In 2021, Medtronic expanded the Class I recall of its MiniMed 600 series insulin pumps. The company offered to replace all of them with a <a href="https://www.benzinga.com/news/21/10/23266202/medtronic-expands-recall-of-minimed-600-series-insulin-pumps" target="_blank" rel="noreferrer noopener">clear retainer ring</a>.
Price Action: MDT stock closed at $87.72 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41183612/nvidias-top-brass-unloaded-significant-stock-in-2024-amid-ai-spending-and-chip-delays" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Top Brass Unloaded Significant Stock In 2024 Amid AI Spending and Chip Delays</a>.</li>
</ul>
Image: Wikimedia Commons

Health Care

Medtronic Recalls MiniMed Pump Due To Battery Life Concerns

Medtronic Voluntarily Issued A Field Action Notifying Of Its MiniMed 600 Series Or 700 Series Insulin Pumps With Potential Risks Of Shortened Pump Battery Life

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 23.26% since its last report. The company recently reported that it has 12.70 million shares sold short, which is 0.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727893813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Medtronic's Recent Short Interest

Evercore ISI Group analyst Vijay Kumar maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $100 to $104.

Evercore ISI Group Maintains Outperform on Medtronic, Raises Price Target to $104

Citigroup analyst Joanne Wuensch maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $85 to $92.

Citigroup Maintains Neutral on Medtronic, Raises Price Target to $92

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect&#x2122; Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.
Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.
"Real-world evidence on chronic lesion formation and durability is critical as use of PFA for the treatment of Afib rapidly increases, making these results impactful and timely for the electrophysiology community," said Devi Nair, M.D., FHRS, Director of Cardiac Electrophysiology &amp; Research, St. Bernard's Medical Center &amp; Arrhythmia Research Group, Jonesboro, Arkansas. "Our research shows that treatment with PulseSelect results in durable lesion formation, which is the cornerstone of successful pulmonary vein isolation and an important addition to previous evidence establishing the safety and effectiveness of this technology."
About the Study A total of 25 AFib patients with persistent or paroxysmal AFib (56% paroxysmal, 52% male, 69±9 years) undergoing pulmonary vein isolation (PVI) with the PulseSelect PFA System were evaluated. Invasive remapping conducted in all patients (57±9 days post-ablation) demonstrated durable isolation in 98% of PVs (102/104), and 96% of patients (24/25) had all veins isolated.
All index ablation procedures were conducted using intracardiac echocardiography and electroanatomical mapping (EAM) without fluoroscopy. General anesthesia was used in 24 of 25 patients, and all patients were discharged on the same day. Average skin-to-skin procedure time was 36 minutes. Acute PV isolation was achieved in 100% of patients. There were no complications during an average follow-up of 74 days.
PulseSelect Global Expansion Broad adoption of PulseSelect continues globally, with more than 10,000 cases performed worldwide. In the Asia Pacific (APAC) region, milestones include regulatory approvals in China and Australia and launch in Japan following reimbursement approval.
Prof. Hiroshi Tada, Professor of the Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Japan, and President of the Japanese Heart Rhythm Society, said "PulseSelect is the first PFA catheter to receive reimbursement approval in Japan based on clinical trial results that include Japanese patients. We believe that the future widespread availability of this breakthrough technology under insurance coverage will be of great significance in the history of arrhythmia treatment in Japan."
"These important results clearly address the durability question and add to the real-world evidence for PulseSelect," said Rebecca Seidel, president, Cardiac Ablations Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "With expansion in new markets across the Asia Pacific region, physicians around the world are experiencing the benefits of PulseSelect, including proven safety, efficacy, efficiency and now durability as well. We are thrilled to provide this important tool to physicians for the treatment of patients with AFib."
AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide.1 Afib is a progressive disease, often beginning as paroxysmal AFib (presents intermittently) and progressing to persistent (lasts for more than 7+ days without stopping). As the disease progresses, the risk of serious complications including heart failure, stroke and risk of death increases.2-5

Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability

Investors with a lot of money to spend have taken a bearish stance on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MDT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Medtronic.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,528, and 9, calls, for a total amount of $634,635.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $82.5 and $97.5 for Medtronic, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $97.5 in the last 30 days. 
<h3>Medtronic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121678_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.19</td>
<td>$1.19</td>
<td>$90.00</td>
<td>$143.3K</td>
<td>7.6K</td>
<td>1.7K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.16</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$92.50</td>
<td>$86.9K</td>
<td>592</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>960</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>660</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.2</td>
<td>$2.11</td>
<td>$2.11</td>
<td>$92.50</td>
<td>$63.3K</td>
<td>592</td>
<td>60</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
After a thorough review of the options trading surrounding Medtronic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Medtronic's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,862,431, with MDT's price up by 0.74%, positioned at $90.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 57 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Medtronic Unusual Options Activity For September 23

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price target at $...

Medtronic's Innovative Affera System Gains FDA Approval, Boosting EP Market Prospects

DexCom Growing Into Its Valuation, But Still No Bargain

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson's rating is based on th...

Medtronic's Sphere-9: Promising FDA Approval Amidst Production Uncertainties

Apple reportedly tests a blood sugar app

Raymond James notes that investigators presented EARLY TAVR data at the transcatheter Cardiovascuar Therapeutics confidence. The trial studied the ...

Raymond James says Edwards' EARLY TAVR data also positive for Medtronic, Abbott

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Medtronic (MDT – Research Report) yesterday and set a price target of $106.00. The c...

Medtronic (MDT) Gets a Buy from Wells Fargo

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

ClearPoint Neuro: Investors Enamored With Its Growth Prospects

Robotics is pivotal in the automation revolution, driving substantial growth in diverse sectors like air defense and healthcare. Therefore, it could be wise to consider fundamentally strong robotics stocks like RTX (RTX), Stryker (SYK), and Medtronic (MDT). Read on... The robotics market is leading the automation revolution, driven by groundbreaking innovations in AI, machine learning, collaborative robots, enhanced safety features, and autonomous systems. With such rapid advancements, investing in this market presents a compelling opportunity for substantial growth.
These advancements are reshaping industries such as air defense, as well as the MedTech and medical sectors, boosting productivity, bridging skill gaps, and revolutionizing healthcare. In this evolving landscape, investors might want to consider strong robotics stocks that are driving this transformation: RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>), Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>), and Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>).
The robotics revolution is reshaping air defense, leveraging AI in soldier training, aerial vehicles (UAVs), and logistics to boost combat effectiveness and cybersecurity. With enhanced drones, autonomous systems, and EMP tech, modern defense becomes more agile, boosting optimism in the robotics sector. The global robotics market is set to grow at a 14.7% CAGR, reaching <a href="https://www.precedenceresearch.com/robotics-technology-market">$283.19 billion by 2032</a>.
Furthermore, robotics is transforming healthcare by enabling precise surgeries, speeding diagnoses, enhancing mobility, supporting rehabilitation, and increasing accessibility through telemedicine. These innovations boost patient care and market growth. As a result, this year, the global medical service robotics market reached $11.2 billion and is expected to grow to nearly <a href="https://www.statista.com/forecasts/1321270/worldwide-medical-robotics-market-size#:~:text=In%202024%2C%20the%20global%20medical,billion%20U.S.%20dollars%20by%202028.">$21 billion by 2028</a>.
Considering these trends, let's assess the fundamentals of the abovementioned robotics stocks.
RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>)
RTX is an aerospace and defense company that provides systems and services for commercial, military, and government customers internationally. It operates through three segments: Collins Aerospace, Pratt &amp; Whitney, and Raytheon.
On October 15, 2024, RTX's Raytheon achieved full-rate production approval for its SM-3 Block IIA missile, marking a key milestone in its missile defense partnership with Japan.
On October 10, 2024, RTX's Raytheon was awarded a $736 million U.S. Navy contract to produce AIM-9X Sidewinder missiles, enhancing short-range missile defense capabilities.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/l/levered-free-cash-flow.asp">levered FCF</a> margin, RTX's 12.99% is 98.4% higher than the 6.55% industry average. Likewise, its 3.28% trailing-12-month Capex / Sales is 13.3% higher than the 2.89% industry average.
RTX's sales for the second quarter ending June 30, 2024, increased 7.7% from the year to $19.72 billion. Its adjusted net income attributable to common shareholders remained flat year-over-year at $1.90 billion, while its EPS rose 9.3% year-over-year to $1.41. Additionally, the company's free cash flow increased significantly from the previous year to $2.20 billion.
Street expects RTX's EPS and revenue for the quarter ended September 30, 2024, to increase 7.1% and 47.2% year-over-year to $1.34 and $19.82 billion, respectively. It surpassed the Street EPS estimates in each of the trailing four quarters. The stock has gained 70.2% over the past year to close the last trading session at $125.75.
RTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong fundamentals. It has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #19 out of 73 stocks in the <a href="https://stocknews.com/category/air-defense/">Air/Defense Services</a> industry. It has a B grade for Growth, Momentum, and Sentiment. To see RTX's Value, Stability, and Quality ratings, <a href="https://stocknews.com/stock/RTX/">click here</a>.
Stryker Corporation (<a href="https://stocknews.com/stock/SYK/">SYK</a>)
SYK operates as a medical technology company. The company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine.
On October 1, 2024, SYK completed the acquisition of Vertos Medical, enhancing its non-surgical interventional pain management solutions for chronic lower back pain.
Andy Pierce, Group President of MedSurg and Neurotechnology, at SYK, said, "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers."
On August 17, 2024, SYK completed its acquisition of care.ai, expanding its healthcare IT offerings with AI-assisted virtual care and smart room technology solutions.
In terms of the trailing-12-month EBIT margin, SYK's 20.71% is 679.3% higher than the 2.66% industry average. Similarly, its 0.56x trailing-12-month asset turnover ratio is 35.9% higher than the 0.41x industry average. Moreover, its 10.29% trailing-12-month levered FCF margin is 639.8% higher than the 1.39% industry average.
In the second quarter that ended on June 30, 2024, SYK's net sales increased 8.5% year-over-year to $5.42 billion. Likewise, its adjusted gross profit grew 9.1% from the year-ago value to $3.48 billion.
SYK's adjusted operating income was $1.33 billion, an increase of 9.7% from the previous year's period. In addition, the company's net earnings and adjusted EPS amounted to $1.09 billion and $2.81, up 11.2% and 10.6% year-over-year, respectively.
For the quarter ended September 30, 2024, SYK's EPS and revenue are expected to increase 12.7% and 9.5% year-over-year to $2.77 and $5.37 billion, respectively. SYK surpassed consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 33.8% to close the last trading session at $359.73.
SYK's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
SYK has a B grade for Growth, Stability, and Sentiment. It is ranked #30 out of 135 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/SYK/">Click here</a> to access additional ratings of SYK for Value, Momentum, and Quality.
Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and The Diabetes Operating Unit segment.
On September 25, 2024, MDT announced the commercial launch of new technologies in its AiBLE spine surgery ecosystem, including software, hardware, and imaging advancements. The company also unveiled a partnership with Siemens Healthineers to integrate advanced imaging solutions for spine care.
On August 7, 2024, MDT announced FDA approval of its Simplera continuous glucose monitor (CGM) and a global partnership with Abbott to expand CGM offerings for diabetes management. This partnership will integrate Abbott's CGM technology with MDT's insulin delivery systems.
In terms of the trailing-12-month gross profit margin, MDT's 65.52% is 13.6% higher than the 57.66% industry average. Its 27.67% trailing-12-month EBITDA margin is 338.3% higher than the 6.31% industry average. Likewise, the stock's 19.57% trailing-12-month EBIT margin is 636.4% higher than the 2.66% industry average.
MDT's net sales for its first quarter ended July 26, 2024, increased 2.8% from the prior-year period to $7.92 billion. The company's non-GAAP operating profit grew 2.3% over the prior-year quarter to $1.95 billion. In addition, its attributable net income rose 31.7% from the year-ago value to $1.04 billion, and its non-GAAP EPS stood at $1.23, up 2.5% year-over-year.
Analysts expect MDT's revenue for the quarter ending October 31, 2024, to increase 3.7% year-over-year to $8.28 billion. Its EPS for the quarter ending January 31, 2025, is expected to grow 5.5% year-over-year to $1.37. It surpassed the Street EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 23.3% to close the last trading session at $89.79.
MDT's POWR Ratings reflect robust prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #16 in the Medical - Devices &amp; Equipment industry. It has a B grade for Stability and Sentiment. <a href="https://stocknews.com/stock/MDT/">Click here</a> to see MDT's Growth, Value, Momentum, and Quality ratings.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
RTX shares were trading at $126.03 per share on Friday afternoon, up $0.28 (+0.22%). Year-to-date, RTX has gained 52.49%, versus a 24.08% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/rtx-syk-mdt-3-robotics-stocks-powering-the-automation-revolution/>3 Robotics Stocks Powering the Automation Revolution</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Robotics Stocks Powering the Automation Revolution

Axonics' Market Growth Strengthens Boston Scientific's Future

AAPL

AXNX

CLPT

DXCM

SENS

Screenshot 2024-10-03 at 5.30.47 PM

GCTK

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Medtronic

Vendite allo scoperto

Medtronic (NYSE:MDT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO